Intersection ENT (XENT Free Report) came out with a quarterly loss of $ 0.49 per share compared to Zacks’ consensus estimate of a loss of $ 0.42. This compares to a loss of $ 0.65 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents a surprise earnings of -16.67%. A quarter ago, this absorbable nasal implant maker was expected to post a loss of $ 0.42 per share when it actually recorded a loss of $ 0.51, delivering a surprise of -21.43%.

In the past four quarters, the company has exceeded consensus EPS estimates only once.

Intersect ENT, which is part of the Zacks Medical – Instruments industry, reported revenue of $ 27.35 million for the quarter ended June 2021, beating Zacks’ consensus estimate by 0.47%. This compares to a year ago revenue of $ 9.78 million. The company has exceeded consensus revenue estimates four times in the past four quarters.

The sustainability of the immediate stock price movement based on recently released numbers and future earnings expectations will depend primarily on management feedback on the profit call.

Intersect ENT stocks have added about 7.1% year-to-date against the S&P 500’s 17.9% gain.

What’s next for Intersect ENT?

While Intersect ENT has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?

There are no easy answers to this key question, but a reliable metric that can help investors solve this problem is the company’s earnings outlook. This includes not only the current consensus earnings expectations for the coming quarter (s), but also how those expectations have changed in recent times.

Empirical research shows a strong correlation between short-term stock market movements and trends in earnings estimate revisions. Investors can follow these revisions on their own or rely on a proven scoring tool like Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Prior to this publication of the results, the trend in revised estimates for Intersect ENT was mixed. While the magnitude and direction of estimate revisions may change as a result of the company’s just-released earnings report, the current status translates to a Zacks (Hold) rank of 3 for the stock. Thus, stocks are expected to move in line with the market in the near future. You can see the full list of Zacks # 1 Rank (Strong Buy) stocks today here.

It will be interesting to see how the estimates for the next quarters and the current year evolve in the days to come. Current consensus estimate of EPS is $ 0.41 on $ 30.51 million of revenue for the coming quarter and $ -1.71 on $ 118.95 million of revenue for the current year .

Investors should be aware that the outlook for the sector can also have a significant impact on the performance of the stock. In terms of Zacks industry rankings, Medical – Instruments is currently in the lowest 28% of Zacks 250+ industries. Our research shows that the top 50% of industries ranked by Zacks outperform the bottom 50% by a factor of more than 2 to 1.

Leave a Reply

Your email address will not be published.